(S)-nadifloxacin and Disease-Models--Animal

Fluoroquinolones are reported to possess immunomodulatory activity; hence, a novel benzoquinolizine fluoroquinolone, levonadifloxacin, was evaluated in lipopolysaccharide-stimulated human whole-blood (HWB) and mouse acute lung injury (ALI) models. Levonadifloxacin significantly mitigated the inflammatory responses in an HWB assay through inhibition of proinflammatory cytokines and in the ALI model by lowering lung total white blood cell count, myeloperoxidase, and cytokine levels. The immunomodulatory effect of levonadifloxacin, along with promising antibacterial activity, is expected to provide clinical benefits in the treatment of infections.

Topics: Acute Lung Injury; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacteria; Cytokines; Disease Models, Animal; Humans; Immunologic Factors; Immunomodulation; Inflammation; Leukocyte Count; Lipopolysaccharides; Mice; Microbial Sensitivity Tests; Peroxidase; Quinolizines; Quinolones